Abstract:Recent advances in high-resolution mass spectrometry-based proteomics have improved our understanding of lysine acetylation in proteins, including histones and non-histone proteins. Lysine acetylation, a reversible post-translational modification, is catalyzed by lysine acetyltransferases (KATs) and lysine deacetylases (KDACs). Proteins comprising evolutionarily conserved bromodomains (BRDs) recognize these acetylated lysine residues and consequently activate transcription. Lysine acetylation regulates almost all cellular processes, including transcription, cell cycle progression, and metabolic functions. Studies have reported the aberrant expression, translocation, and mutation of genes encoding lysine acetylation regulators in various cancers, including digestive tract cancers. These dysregulated lysine acetylation regulators contribute to the pathogenesis of digestive system cancers by modulating the expression and activity of cancer-related genes or pathways. Several inhibitors targeting KATs, KDACs, and BRDs are currently in preclinical trials and have demonstrated anti-cancer effects. Digestive tract cancers, including encompass esophageal, gastric, colorectal, liver, and pancreatic cancers, represent a group of heterogeneous malignancies. However, these cancers are typically diagnosed at an advanced stage owing to the lack of early symptoms and are consequently associated with poor 5-year survival rates. Thus, there is an urgent need to identify novel biomarkers for early detection, as well as to accurately predict the clinical outcomes and identify effective therapeutic targets for these malignancies. Although the role of lysine acetylation in digestive tract cancers remains unclear, further analysis could improve our understanding of its role in the pathogenesis of digestive tract cancers. This review aims to summarize the implications and pathogenic mechanisms of lysine acetylation dysregulation in digestive tract cancers, as well as its potential clinical applications.

Protein Lysine Acetylation Guards Metabolic Homeostasis to Fight Against Cancer

Acetylation Control Of Cancer Cell Metabolism

Regulation of cell metabolism by lysine acetylation

Acetyl-CoA Regulates Lipid Metabolism and Histone Acetylation Modification in Cancer

Impact of Acetylation on Tumor Metabolism

Regulation of Cellular Metabolism by Protein Lysine Acetylation

Regulation of cancer metabolism by O-GlcNAcylation

Metabolism is Regulated by Protein Acetylation

Dysregulation of lysine acetylation in the pathogenesis of digestive tract cancers and its clinical applications

Acetyl-CoA Metabolism As a Therapeutic Target for Cancer

Oncometabolites drive tumorigenesis by enhancing protein acylation: from chromosomal remodelling to nonhistone modification

The role of protein acetylation in carcinogenesis and targeted drug discovery

Acetylation Regulation of Cellular Metabolism by Protein Lysine

Targeting the acetylation signaling pathway in cancer therapy

Acetylation Control of Metabolic Enzymes in Cancer: an Updated Version

Acetylation in pathogenesis: Revealing emerging mechanisms and therapeutic prospects

Regulation of metabolism by protein lysine acetylation modification

Molecular Characterization and Clinical Relevance of Lysine Acetylation Regulators in Urological Cancers

A glimpse into novel acylations and their emerging role in regulating cancer metastasis

Regulation of epithelial-mesenchymal transition by protein lysine acetylation

Acetyl-CoA metabolism in cancer